Experimental and clinical approaches for optimization of the graft-versus-leukemia effect

Nature Clinical Practice Oncology

Volumn 4, Issue 7, 2007, Pages 404-414

  Sprangers, Ben ^a   Van Wijmeersch, Bart ^a   Fevery, Sabine ^a   Waer, Mark ^a   Billiau, An D ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; BORTEZOMIB; CYTOKINE; FINGOLIMOD; HISTONE DEACETYLASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LEUCYLLEUCINE METHYL ESTER; MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; RAPAMYCIN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIGEN PRESENTING CELL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL STUDY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; EFFECTOR CELL; EXPERIMENTAL STUDY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LEUKEMIA RELAPSE; LYMPHOCYTE DEPLETION; NATURAL KILLER CELL; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK REDUCTION; SUICIDE GENE THERAPY; ULTRAVIOLET A RADIATION;

ANIMALS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LEUKEMIA, EXPERIMENTAL; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 34447274519     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0848     Document Type: Review

References (110)

1. Barnes DW et al. (1956) Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J 32: 626-627
2. Weiden PL et al. (1981) Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304: 1529-1533
3. Horowitz MM et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-562
4. Slavin S et al. (1988) Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man [abstract #1540]. Blood 72 (Suppl 1): 407a
5. Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411: 385-389
6. Bleakley M et al. (2004) Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 4: 371-380
7. Kolb HJ et al. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462-2465
8. Hambach L et al. (2005) Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 17: 202-210
9. Marijt WA et al. (2003) Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 100: 2742-2747
10. Yotnda P et al. (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101: 2290-2296
11. + T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation 71: 1131-1137
12. Clark RE et al. (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98: 2887-2893
13. Molldrem JJ et al. (2003) Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 111: 639-647
14. Ruggeri L et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100
15. Ljunggren HG et al. (1990) In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 11: 237-244
16. Parham P et al. (2003) Alloreactive killer cells: Hindrance and help for haematopoietic transplants. Nat Rev Immunol 3: 108-122
17. + cells for prevention of graft-versus-host disease after bone marrow transplantation: A randomized controlled trial. Transplantation 57: 82-87
18. Giralt SA et al. (1994) Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 84: 3603-3612
19. Clift RA et al. (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 76: 1867-1871
20. McSweeney PA et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390-3400
21. Sullivan KM et al. (1989) Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320: 828-834
22. Slavin S et al. (1995) Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral Blood lymphocytes. Exp Hematol 23: 1553-1562
23. Collins RH Jr et al. (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15: 433-444
24. Dazzi F et al. (2000) Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96: 2712-2716
25. Kolb HJ et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 2041-2050
26. Porter DL et al. (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330: 100-106
27. Levine JE et al. (2002) Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 20: 405-412
28. Porter DL et al. (1999) Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant 5: 253-261
29. Champlin R et al. (2000) Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111: 18-29
30. Giralt S et al. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 4531-4536
31. Whiteway A et al. (2003) Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission. Br J Haematol 120: 442-451
32. Choudhury A et al. (1997) Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89: 1133-1142
33. Sehn LH et al. (1999) Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Impact of donor lymphocyte infusion. J Clin Oncol 17: 561-568
34. Marks DI et al. (2000) T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 6: 646-653
35. Childs R et al. (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 94: 3234-3241
36. Keil F et al. (1997) Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia. Blood 89: 3113-3117
37. Mapara MY et al. (2002) Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 100: 1903-1909
38. Billiau AD et al. (2002) Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood 100: 1894-1902
39. Shlomchik WD et al. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 412-415
40. Shiobara S et al. (2001) Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: Indications and dose escalation. Ther Apher 5 40-45
41. Porter D et al. (2006) Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion. Semin Hematol 43: 53-61
42. Dey BR et al. (2005) Anti-tumour response despite loss of donor chimaerism in patients treated with nonmyeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 128: 351-359
43. + T cells. J Immunol 175: 665-676
44. Badros A et al. (2001) High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 97: 2574-2579
45. Johnson BD et al. (1995) Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 85: 3302-3312
46. Antin JH et al. (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80: 2964-2968
47. Chakraverty R et al. (2006) An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 203: 2021-2031
48. Bethge WA et al. (2004) Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 103: 790-795
49. Dey BR et al. (2003) Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 9: 320-329
50. Marks DI et al. (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100: 3108-3114
51. Mackinnon S et al. (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86: 1261-1268
52. Peggs KS et al. (2004) Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism, and disease responses. Blood 103: 1548-1556
53. Dazzi F et al. (2000) Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95: 67-71
54. Novitzky N et al. (2000) Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: A therapeutic strategy. Transplantation 69: 1358-1363
55. Bacigalupo A et al. (1997) Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 19: 927-932
56. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 8: 51-58
57. OKunewick JP et al. (1991) The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia. Bone Marrow Transplant 8: 445-452
58. Johnson BD et al. (1999) Graft-vs-host and graft-vs-leukemia reactions after delayed infusions of donor T-subsets. Biol Blood Marrow Transplant 5: 123-132
59. Porter DL et al. (1999) The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 50: 369-386
60. + cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: Implications for graft-versus-leukemia reactivity. Blood 86: 2821-2828
61. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76: 418-423
62. + cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: A pilot study. Bone Marrow Transplant 34: 123-128
63. Amrolia PJ et al. (2003) Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102: 2292-2299
64. Amrolia PJ et al. (2005) Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation. Cytotherapy 7: 116-125
65. Koh MB et al. (1999) Selective removal of alloreactive cells from haematopoietic stem cell grafts: Graft engineering for GVHD prophylaxis. Bone Marrow Transplant 23: 1071-1079
66. Martins SL et al. (2004) Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104: 3429-3436
67. Guimond M et al. (2002) P-glycoprotein targeting: A unique strategy to selectively eliminate immunoreactive T cells. Blood 100: 375-382
68. Godfrey WR et al. (2004) Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 103: 1158-1165
69. + T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci USA 100: 1180-1184
70. Bachar-Lustig E et al. (2003) Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: Synergism with rapamycin and BM cell dose. Blood 102: 1943-1950
71. Arditti FD et al. (2005) Eradication of B-CLL by autologous and allogeneic host nonreactive anti-third-party CTLs. Blood 105 3365-3371
72. Moss P et al. (2005) Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol 5: 9-20
73. Oosten LE et al. (2004) Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood 104: 224-226
74. Fontaine P et al. (2001) Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 7: 789-794
75. Buhmann R et al. (1999) CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 93: 1992-2002
76. Schultze JL et al. (1995) Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 92: 8200-8204
77. Stanislawski T et al. (2001) Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2 962-970
78. Xue SA et al. (2005) Elimination of human leukemia cells in NOD/ SCID mice by WT1-TCR gene-transduced human T cells. Blood 106 3062-3067
79. Hacein-Bey-Abina S et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419
80. Bonini C et al. (2003) Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9: 367-369
81. Bonini C et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 1719-1724
82. Tiberghien P et al. (2001) Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97: 63-72
83. Verzeletti S et al. (1998) Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors. Hum Gene Ther 9: 2243-2251
84. Berger C et al. (2006) Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107: 2294-2302
85. Thomis DC et al. (2001) A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97 1249-1257
86. Junker K et al. (2003) Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes. Gene Ther 10: 1189-1197
87. Carlotti F et al. (2005) Development of an inducible suicide gene system based on human caspase 8. Cancer Gene Ther 12: 627-639
88. Waller EK et al. (1999) Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. Blood 94: 3222-3233
89. Truitt RL et al. (1999) Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 163: 5145-5156
90. Waller EK et al. (2000) New strategies in allogeneic stem cell transplantation: Immunotherapy using irradiated allogeneic T cells. Bone Marrow Transplant 25 (Suppl 2): S20-S24
91. Fowler DH et al. (2006) Phase I clinical trial of costimulated, IL-4 polarized donor CD4(+) T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 12: 1150-1160
92. Porter DL et al. (2006) A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107: 1325-1331
93. Wood KJ et al. (2003) Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3: 199-210
94. Hoffmann P et al. (2002) Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196: 389-399
95. Taylor PA et al. (2002) The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493-3499
96. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9: 1144-1150
97. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 112: 1688-1696
98. Jones SC et al. (2003) Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 9: 243-256
99. + regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease. Biol Blood Marrow Transplant 10: 748-760
100. Hoffmann P et al. (2004) Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 104 895-903
101. Sato K et al. (2003) Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18: 367-379
102. Slavin S et al. (1978) Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation. J Exp Med 147: 963-972
103. Lan F et al. (2003) Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: The role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant 9: 355-363
104. Lowsky R et al. (2005) Protective conditioning for acute graft-versus-host disease. N Engl J Med 353: 1321-1331
105. Bronte V et al. (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654
106. + early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: Possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. Blood 102: 740-748
107. Reddy P et al. (2005) A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 11: 1244-1249
108. Merad M et al. (2004) Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 10: 510-517
109. Harrison BD et al. (2001) Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia. Blood 97: 2764-2771
110. Giebel S et al. (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102: 814-819